Abstract
Background: Abdominal aortic aneurysms (AAA) are life-threatening because of the potential for rupture, resulting in death. The current standard treatment for AAA is surgery, comprising laparotomic graft replacement and endovascular repair. However, because surgery carries the risk of major complications and re-intervention, drug therapies are desirable because they may reduce the occurrence of enlargement and rupture.
Objective: Recent research shows that the progression of AAA is related to inflammatory reactions, especially those in the NF-κB pathway. Omega-3 polyunsaturated fatty acids (PUFA) show antiinflammatory effects. Some derivatives of omega-3 PUFA are known as specialized pro-resolving lipid mediators (SPM) such as resolvins. They play an important role in resolving inflammation.
Conclusion: Omega-3 PUFA and SPM may show promised effects for drug treatment of AAA.
Keywords: Abdominal aortic aneurysm (AAA), drug therapy, inflammation, omega-3 polyunsaturated fatty acid (PUFA), resolvin, intraluminal thrombus.
Current Drug Targets
Title:Drug Therapy for Abdominal Aortic Aneurysms Utilizing Omega-3 Unsaturated Fatty Acids and Their Derivatives
Volume: 19 Issue: 11
Author(s): Daisuke Akagi*, Katsuyuki Hoshina, Toshiaki Watanabe and Micheal S. Conte
Affiliation:
- Division of Vascular and Endovascular Surgery, Department of Surgery, Cardiovascular Research Institute, University of California, San Francisco CA 94117,United States
Keywords: Abdominal aortic aneurysm (AAA), drug therapy, inflammation, omega-3 polyunsaturated fatty acid (PUFA), resolvin, intraluminal thrombus.
Abstract: Background: Abdominal aortic aneurysms (AAA) are life-threatening because of the potential for rupture, resulting in death. The current standard treatment for AAA is surgery, comprising laparotomic graft replacement and endovascular repair. However, because surgery carries the risk of major complications and re-intervention, drug therapies are desirable because they may reduce the occurrence of enlargement and rupture.
Objective: Recent research shows that the progression of AAA is related to inflammatory reactions, especially those in the NF-κB pathway. Omega-3 polyunsaturated fatty acids (PUFA) show antiinflammatory effects. Some derivatives of omega-3 PUFA are known as specialized pro-resolving lipid mediators (SPM) such as resolvins. They play an important role in resolving inflammation.
Conclusion: Omega-3 PUFA and SPM may show promised effects for drug treatment of AAA.
Export Options
About this article
Cite this article as:
Akagi Daisuke *, Hoshina Katsuyuki , Watanabe Toshiaki and Conte S. Micheal, Drug Therapy for Abdominal Aortic Aneurysms Utilizing Omega-3 Unsaturated Fatty Acids and Their Derivatives, Current Drug Targets 2018; 19 (11) . https://dx.doi.org/10.2174/1389450118666171013101815
DOI https://dx.doi.org/10.2174/1389450118666171013101815 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Atherosclerotic Renal Artery Stenosis: An Update on Diagnosis and Management
Current Vascular Pharmacology Transseptal Access to the Left Atrium: Tips and Tricks to Keep it Safe Derived from Single Operator Experience and Review of the Literature
Current Cardiology Reviews Endogenous Events Modulating Myogenic Regulation of Cerebrovascular Function
Current Vascular Pharmacology Pathophysiology of Cardiovascular Diseases and the Role of Vitamins, and Herbal Extracts in the Reduction of Cardiovascular Risks
Cardiovascular & Hematological Agents in Medicinal Chemistry Fluid-fluid Levels in Musculoskeletal Tumor Imaging
Current Medical Imaging MicroRNAs as Early Biomarkers in Obesity and Related Metabolic and Cardiovascular Diseases
Current Pharmaceutical Design Inhibitors of the Proteolytic Activity of Urokinase Type Plasminogen Activator
Current Pharmaceutical Design Lipoprotein (a) Management: Lifestyle and Hormones
Current Medicinal Chemistry Patent Selections:
Recent Patents on Anti-Infective Drug Discovery Gender Medicine and Pharmacoeconomics: A Narrative Review of the International Literature of the Last 5 Years. A Revision of Evidences about the Relationship Between Gender and Economic Consumption in Health
Current Pharmaceutical Design Lithium and its Neuroprotective and Neurotrophic Effects: Potential Treatment for Post-Ischemic Stroke Sequelae
Current Drug Targets Relationship Between Hypertension and Atherosclerosis: From a Viewpoint of the Most Potent Vasoconstrictor Human Urotensin II
Current Hypertension Reviews Prevention of Ischemic Stroke: Antithrombotic Therapy in Cardiac Embolism
Current Drug Targets Rho as a Target to Promote Repair: Translation to Clinical Studies with Cethrin
Current Pharmaceutical Design The Correspondence Between Magnetic Resonance Images and the Clinical and Intraoperative Status of Patients with Spinal Tumors
Current Medical Imaging Oxidative Stress and Lipid Peroxidation in Prolonged Users of Methamphetamine
Drug Metabolism Letters Targeting the Role of Lipoprotein (a) in Stroke
Cardiovascular & Hematological Disorders-Drug Targets Utility and Limitations of SP600125, an Inhibitor of Stress-Responsive c-Jun N-Terminal Kinase
Current Enzyme Inhibition Role of AGEs-RAGE System in Cardiovascular Disease
Current Pharmaceutical Design Crosslinked, Polymerized, and PEG-Conjugated Hemoglobin-Based Oxygen Carriers: Clinical Safety and Efficacy of Recent and Current Products
Current Drug Discovery Technologies